GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Jia Jie Biomedical Co Ltd (ROCO:4109) » Definitions » EBIT

Jia Jie Biomedical Co (ROCO:4109) EBIT : NT$226.1 Mil (TTM As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Jia Jie Biomedical Co EBIT?

Jia Jie Biomedical Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was NT$-16.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$226.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jia Jie Biomedical Co's annualized ROC % for the quarter that ended in Dec. 2024 was 3.92%. Jia Jie Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -14.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jia Jie Biomedical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 11.16%.


Jia Jie Biomedical Co EBIT Historical Data

The historical data trend for Jia Jie Biomedical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jia Jie Biomedical Co EBIT Chart

Jia Jie Biomedical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.94 5.35 -4.57 146.90 226.13

Jia Jie Biomedical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 158.46 18.52 219.23 4.68 -16.31

Competitive Comparison of Jia Jie Biomedical Co's EBIT

For the Packaged Foods subindustry, Jia Jie Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jia Jie Biomedical Co's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Jia Jie Biomedical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jia Jie Biomedical Co's EV-to-EBIT falls into.


;
;

Jia Jie Biomedical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$226.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jia Jie Biomedical Co  (ROCO:4109) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jia Jie Biomedical Co's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=42.564 * ( 1 - -5.99% )/( (1161.975 + 1142.389)/ 2 )
=45.1135836/1152.182
=3.92 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1497.075 - 98.483 - ( 263.04 - max(0, 106.614 - 343.231+263.04))
=1161.975

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1482.284 - 108.408 - ( 263.049 - max(0, 116.849 - 348.336+263.049))
=1142.389

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Jia Jie Biomedical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-65.232/( ( (453.338 + max(-32.116, 0)) + (450.753 + max(-37.647, 0)) )/ 2 )
=-65.232/( ( 453.338 + 450.753 )/ 2 )
=-65.232/452.0455
=-14.43 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(31.63 + 30.602 + 9.849) - (98.483 + 0 + 5.714)
=-32.116

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(40.835 + 24.494 + 11.117) - (108.408 + 0 + 5.685)
=-37.647

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jia Jie Biomedical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=226.126/2025.883
=11.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jia Jie Biomedical Co EBIT Related Terms

Thank you for viewing the detailed overview of Jia Jie Biomedical Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Jia Jie Biomedical Co Business Description

Traded in Other Exchanges
N/A
Address
Jiuru 1st Road, 3rd Floor, No. 61, Sanmin District, Kaohsiung City, TWN, 807
Jia Jie Biomedical Co Ltd is a Taiwan-based company. It is engaged in the turtle shellfish, turtle eggs, turtle oil and other turtle food processing manufacturing sales trading business. It has two reportable segments: Taiwan Operating Segment and Mainland China Operating Segment. The Taiwan Operating Segment is mainly engaged in production and distribution segment of nutritional health products and insurance brokerage, while the Mainland China Operating Segment is mainly engaged in the sale of water purification equipment and related parts.

Jia Jie Biomedical Co Headlines

No Headlines